Zobrazeno 1 - 10 of 31 pro vyhledávání: '"Matthias, Bischof"'
1
Akademický článek
Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England
Autor: Diana Weidlich, Laurent Servais, Imran Kausar, Ruth Howells, Matthias Bischof
Publikováno v: Neurology and Therapy, Vol 12, Iss 4, Pp 1205-1220 (2023)
Abstract Introduction We sought to evaluate the cost-effectiveness of newborn screening (NBS) versus no NBS for 5q spinal muscular atrophy (SMA) in England. Methods A cost-utility analysis using a combination of decision tree and Markov model structu
Externí odkaz: https://doaj.org/article/8ba8bf0ac4f94632a823eb63a735fc06
Zobrazit plný text záznamu
2
Akademický článek
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)
Autor: Rebecca Dean, Ivar Jensen, Phil Cyr, Beckley Miller, Benit Maru, Douglas M. Sproule, Douglas E. Feltner, Thomas Wiesner, Daniel C. Malone, Matthias Bischof, Walter Toro, Omar Dabbous
Publikováno v: Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
Background: Recent cost-utility analysis (CUA) models for onasemnogene abeparvovec (Zolgensma®, formerly AVXS-101) in spinal muscular atrophy type 1 (SMA1) differ on key assumptions and results. Objective: To compare the manufacturer’s proprietary
Externí odkaz: https://doaj.org/article/4ff5f47c0a944bf891888597b331385c
Zobrazit plný text záznamu
3
Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands
Autor: Rimma Velikanova, Simon van der Schans, Matthias Bischof, Rudolf Walther van Olden, Maarten Postma, Cornelis Boersma
Publikováno v: Value in Health, 25(10), 1696-1704. ELSEVIER SCIENCE INC
Objectives: Spinal muscular atrophy (SMA) is a rare genetic disorder that causes progressive muscle weakness and paralysis. In its most common and severe form, the majority of untreated infants die before 2 years of age. Early detection and treatment
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cb7834be391e050c34f489cec63623e
https://doi.org/10.1016/j.jval.2022.06.010
Zobrazit plný text záznamu
4
Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis
Autor: Marjolaine Gauthier-Loiselle, Matthias Bischof, Anish Patel, O. Dabbous, Sherry Shi, Martin Cloutier, Mikhail Davidson, Nicole LaMarca, Walter Toro
Publikováno v: Advances in Therapy
Introduction Spinal muscular atrophy (SMA) is a rare, genetic neuromuscular disorder caused by deletion/mutation of the survival motor neuron 1 gene, characterized by progressive loss of motor neurons, resulting in increasing muscular weakness, deter
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c8a8d8dbdd978c253934cf077c8d9b7
http://europepmc.org/articles/PMC8552979
Zobrazit plný text záznamu
6
Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1
Autor: Maria Lorenzi, Matthias Bischof, Eric Druyts, Jennifer M Lee, Chakrapani Balijepalli, O. Dabbous
Publikováno v: Current medical research and opinion. 37(10)
Objective Onasemnogene abeparvovec, a one-time intravenous gene replacement therapy, and nusinersen, an antisense oligonucleotide that requires ongoing intrathecal administration, have been evaluated as treatments for spinal muscular atrophy (SMA) ty
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1777af114c2a3f9016184f63517def05
https://pubmed.ncbi.nlm.nih.gov/34236007
Zobrazit plný text záznamu
7
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)
Autor: Phil Cyr, Matthias Bischof, Daniel C. Malone, Ivar Jensen, Benit Maru, Thomas Wiesner, Rebecca Dean, Walter Toro, Beckley Miller, Douglas E. Feltner, O. Dabbous, Douglas M. Sproule
Publikováno v: Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
Journal of Market Access & Health Policy
article-version (VoR) Version of Record
Background: Recent cost-utility analysis (CUA) models for onasemnogene abeparvovec (Zolgensma®, formerly AVXS-101) in spinal muscular atrophy type 1 (SMA1) differ on key assumptions and results. Objective: To compare the manufacturer’s proprietary
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::897d6b522c3e810f3d6e608db8b4c94e
https://doi.org/10.1080/20016689.2021.1889841
Zobrazit plný text záznamu
8
A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate
Autor: Paul Hodgkins, Juliana Setyawan, Matthias Bischof, Josephine Mauskopf, Evelina Zimovetz, Stephen Beard
Publikováno v: CNS Drugs
Background An economic analysis from the perspective of the UK National Health Service (NHS) evaluated the cost effectiveness of lisdexamfetamine dimesylate (LDX) compared with atomoxetine in children and adolescents with attention-deficit/hyperactiv
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04a39f07a11c70ee7bfccc923235c33e
https://doi.org/10.1007/s40263-016-0354-3
Zobrazit plný text záznamu
9
Probing Chiral Recognition of Enzyme Active Sites with Octahedral Iridium(III) Propeller Complexes
Autor: Eric Meggers, Manfred Jung, Klaus Harms, Matthias Bischof, Melanie Helms, Florian Ritterbusch, Peter Göbel
Publikováno v: European Journal of Inorganic Chemistry. 2015:1654-1659
Chiral bis-cyclometalated octahedral organoiridium(III) complexes were designed to target different classes of enzymes, namely carbonic anhydrases, histone deacetylases, and serine proteases. The stereoselective non-racemic synthesis of selected comp
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fc6caca6d74b0833609ac7f58d7bcc17
https://doi.org/10.1002/ejic.201500087
Zobrazit plný text záznamu
10
Preferential accumulation within tumors and in vivo imaging by functionalized luminescent dendrimer lanthanide complexes
Autor: Marco A. Alcala, Hyounsoo Uh, Yong J. Lee, Ruth A. Modzelewski, Shu Ying Kwan, Kristy A. Gogick, David L. Bartlett, Stéphane Petoud, Adam R. Meier, Matthias Bischof, Chad M. Shade, Timothy G. Strein, Charles K. Brown, Zachary P. Thompson
Publikováno v: Biomaterials
Biomaterials, Elsevier, 2011, 32 (35), pp.9343-52. ⟨10.1016/j.biomaterials.2011.07.076⟩
International audience; We have created a dendrimer complex suitable for preferential accumulation within liver tumors and luminescence imaging by substituting thirty-two naphthalimide fluorophores on the surface of the dendrimer and incorporating ei
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6dfc5e61570f7159bd1a3f284c19a3f
https://doi.org/10.1016/j.biomaterials.2011.07.076
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje